PNT(Delisted)
POINT Biopharma·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PNT
Point Biopharma Global Inc
A company that develops next-generation radioligand therapies for the treatment of cancer
4850 West 78th Street, Indianapolis, IN, 46268
--
POINT Biopharma Global Inc was incorporated as a Delaware corporation on September 18, 2019. They are a late-stage clinical precision oncology company focused on the development and commercialization of next-generation radiopharmaceuticals for the treatment of cancer. Their goal is to make radiopharmaceuticals a treatment option for all cancer patients. They are advancing two Phase 3 assets in prostate cancer and neuroendocrine cancer as well as an early combination of next-generation product candidates.
Company Financials
EPS
PNT has released its 2023 Q3 earnings. EPS was reported at -0.23, versus the expected -0.3, beating expectations. The chart below visualizes how PNT has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
PNT has released its 2023 Q3 earnings report, with revenue of 2.79M, reflecting a YoY change of NaN%, and net profit of -24.77M, showing a YoY change of -3.17%. The Sankey diagram below clearly presents PNT's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
